X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GSK PHARMA ASTRAZENECA PHARMA/
GSK PHARMA
 
P/E (TTM) x 125.4 66.0 189.9% View Chart
P/BV x 19.0 11.6 164.4% View Chart
Dividend Yield % 0.0 1.1 -  

Financials

 ASTRAZENECA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
GSK PHARMA
Mar-17
ASTRAZENECA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2853,838 33.5%   
Low Rs6342,637 24.0%   
Sales per share (Unadj.) Rs189.6354.2 53.5%  
Earnings per share (Unadj.) Rs-0.239.8 -0.5%  
Cash flow per share (Unadj.) Rs3.842.9 9.0%  
Dividends per share (Unadj.) Rs030.00 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs68.6236.9 29.0%  
Shares outstanding (eoy) m25.0084.70 29.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.19.1 55.4%   
Avg P/E ratio x-4,712.781.4 -5,788.2%  
P/CF ratio (eoy) x249.675.5 330.5%  
Price / Book Value ratio x14.013.7 102.3%  
Dividend payout %075.4 0.0%   
Avg Mkt Cap Rs m23,988274,216 8.7%   
No. of employees `0001.64.7 33.2%   
Total wages/salary Rs m1,6054,830 33.2%   
Avg. sales/employee Rs Th3,040.26,387.0 47.6%   
Avg. wages/employee Rs Th1,029.21,028.3 100.1%   
Avg. net profit/employee Rs Th-3.3717.1 -0.5%   
INCOME DATA
Net Sales Rs m4,74030,000 15.8%  
Other income Rs m92728 12.6%   
Total revenues Rs m4,83230,728 15.7%   
Gross profit Rs m-1304,190 -3.1%  
Depreciation Rs m101263 38.5%   
Interest Rs m00-   
Profit before tax Rs m-1394,655 -3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m139457 30.4%   
Tax Rs m51,744 0.3%   
Profit after tax Rs m-53,368 -0.2%  
Gross profit margin %-2.714.0 -19.6%  
Effective tax rate %-3.737.5 -9.8%   
Net profit margin %-0.111.2 -1.0%  
BALANCE SHEET DATA
Current assets Rs m2,72616,742 16.3%   
Current liabilities Rs m2,4357,202 33.8%   
Net working cap to sales %6.131.8 19.3%  
Current ratio x1.12.3 48.2%  
Inventory Days Days7452 142.3%  
Debtors Days Days4121 196.1%  
Net fixed assets Rs m1,0358,635 12.0%   
Share capital Rs m50847 5.9%   
"Free" reserves Rs m94219,222 4.9%   
Net worth Rs m1,71620,069 8.6%   
Long term debt Rs m010 0.0%   
Total assets Rs m4,15630,038 13.8%  
Interest coverage xNMNM-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.11.0 114.2%   
Return on assets %-0.111.2 -1.1%  
Return on equity %-0.316.8 -1.8%  
Return on capital %025.5 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m375528 70.9%   
Fx outflow Rs m4707,193 6.5%   
Net fx Rs m-96-6,665 1.4%   
CASH FLOW
From Operations Rs m-82,360 -0.3%  
From Investments Rs m-1463,008 -4.8%  
From Financial Activity Rs m862-5,108 -16.9%  
Net Cashflow Rs m709260 272.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 15.7 23.8 66.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 102,036 12.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   SUN PHARMA  DR. REDDYS LAB  ABBOTT INDIA  UNICHEM LAB  MERCK LTD  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Trade War Fears; Widening of Trade Deficit and Top Stocks in Action Today(Pre-Open)

Indian share markets trimmed their day's losses and ended flat on Friday amid weakness in their Asian peers, that wobbled on Friday as investors braced for US tariffs against China.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jun 15, 2018 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS